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ABSTRACT Some noncompetitive inhibitors (e.g., ganglionic blockers) exhibit selectivity for the inhibition of neuronal
nicotinic acetylcholine receptors (nAChRs). This study characterizes the mechanism of selective long-term inhibition of
neuronal and muscle-neuronal chimeric nAChRs by bis(2,2,6,6-tetramethyl-4-piperidinyl) sebacate (bis-TMP-10 or BTMPS),
a bifunctional form of the potent ganglionic blocker tetramethylpiperidine. Long-term inhibition of neuronal nAChRs by
bis-TMP-10 has been previously demonstrated to arise, at least in part, from the binding of the bis compound to neuronal
-subunits. In this study, long-term inhibition is demonstrated to be dependent upon the presence of sequence element(s)
within the pore-lining second transmembrane domain (tm2) of neuronal -subunits; however, the inhibitor binding site itself
does not appear to be contained within the segment of the channel pore influenced by the membrane electric field.
Specifically, our results imply that bis-TMP-10 interacts with an activation-sensitive element, the availability of which may be
regulated by a sequence in the tm2 domain. Furthermore, we demonstrate a compound length requirement for long-term
inhibition that would be consistent with binding to multiple sites located on the extracellular portion of the receptor.
INTRODUCTION
Neuronal nicotinic acetylcholine receptors (nAChRs) are
pentameric complexes (Anand et al., 1991, Cooper et al.,
1991) and share a considerable number of structural and
functional features with muscle-type nAChRs. Structural
similarities of individual subunits include a large amino-
terminal extracellular domain followed by four putative
transmembrane segments with a large intracellular domain
between transmembrane domains three and four (for review,
see Changeux et al., 1992; Karlin and Akabas, 1995).
Whereas muscle-type nAChRs are composed of four dis-
tinct proteins (1, 1,  or , and  in the ratio of 2:1:1:1),
functional neuronal nAChRs can be composed of as few as
two (- heteromers) or, in some cases, one class of subunit
(-subunit homomers). Eight different genes encoding pu-
tative neuronal -subunits (2–9) and three different
genes (2–4) coding for putative -subunits have been
cloned to date. Pairwise injection of the neuronal -subunit
genes 2, 3, 4, and, in some instances, 6 with the
-subunit genes 2 or 4 provides for the expression of
receptors with pharmacologically and physiologically dis-
tinct activation profiles in Xenopus oocytes (Gerzanich et
al., 1997; Luetje and Patrick, 1991). This situation both
simplifies the study of heterologously expressed receptor
subtypes and complicates efforts to assign specific func-
tional correlations between heterologously expressed recep-
tor subtypes and the receptor subtypes expressed in vivo.
Studies examining the subunit composition of peripheral or
ganglionic neuronal nAChRs have shown that receptors
may include the 3, 5, 4, and/or 2 subunits (Conroy and
Berg, 1995). It has been demonstrated that inclusion or
exclusion of particular subunits will confer particular func-
tional roles and pharmacological sensitivities on nAChRs
(for review, see Papke, 1993; Sargent, 1993). In keeping
with this idea, certain classes of noncompetitive inhibitors
known as ganglionic blockers show selectivity for the inhi-
bition of neuronal nAChRs.
The ganglion blocking activity of two such compounds,
2,2,6,6-tetramethylpiperidine (TMP) and 1,2,2,6,6-penta-
methylpiperidine or pempidine (PMP), has been well doc-
umented in the literature (Lee et al., 1958; Spinks and
Young, 1958). More recently, it was reported that neuronal
nAChRs exhibit more prolonged inhibition in response to
co-application of ACh with a bifunctional analog of TMP,
bis(2,2,6,6-tetramethyl-4-piperidinyl sebacate (bis-TMP-10
or BTMPS), whereas muscle-type nAChRs recover com-
pletely from inhibition within 5 min (Papke et al., 1994).
Furthermore, inhibition of neuronal nAChRs by bis-
TMP-10 was demonstrated to be use dependent and have an
approximate IC50 of 200 nM under experimental conditions
of high popen. In addition, the time course of recovery from
inhibition was shown to be dependent on both the class of
-subunit present (1 or 4/2) and, for the  and 
subunit combinations, the presence or absence of the -sub-
unit (Francis and Papke, 1996; Papke et al., 1994). Bis-
TMP-10 is a member of the bis-TMP-n series of com-
pounds, which share a common structure consisting of a
symmetrical diester of methylated piperidinol rings linked
by an aliphatic diacid chain containing n carbons. Because
of the bifunctional nature of bis-TMP-10, it was hypothe-
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sized that long-term inhibition arises as a result of the
potential for binding of the piperidinol rings to distinct sites.
In the case of muscle-type nAChRs, a number of inves-
tigators have used noncompetitive inhibitors in conjunction
with site-directed mutagenesis or photoaffinity labeling as
probes for structure. These studies have localized the bind-
ing of noncompetitive blockers of muscle-type nAChRs to
the putative pore-lining second transmembrane domain
(tm2) or the short extracellular loop (ecl) region between
tm2 and transmembrane domain 3 (Charnet et al., 1990;
DiPaola et al., 1990; Giraudat et al., 1986; Giraudat et al.,
1987; Leonard et al., 1988; Pedersen et al., 1992; White and
Cohen, 1992). Recently, more detailed insights regarding
structure-function relationships have been obtained either
by examination of the accessibility of substituted cysteines
to covalent modification or by examination of the functional
effects of unnatural amino acid incorporation (Akabas et al.,
1992, 1994; Kearney et al., 1996).
The experiments described in the present study seek to
extend the analysis of structure-function relationships to
neuronal nAChRs by examining subunit-specific determi-
nants of sensitivity to use-dependent inhibition. To charac-
terize the mechanism for the selective long-term inhibition
of neuronal nAChRs, we have created a pair of chimeric
-subunits that exchange eight amino acids of tm2 between
muscle (1) and neuronal -subunits (4 in this case) and a
third chimeric -subunit in which eight amino acids of the
4 subunit ecl region is replaced with the homologous
sequence from 1.
Long-term inhibition of neuronal nAChRs by bis-
TMP-10 is shown to be dependent upon the -subunit tm2
region, although apparently independent of binding to ele-
ments of tm2 located within the membrane electric field or
accessible to open-channel blockers. Because the inhibition
is use dependent, this observation implies binding to sites
for which availability depends both upon channel opening
and interactions with specific sequence elements in tm2.
These findings highlight the dynamic nature of channel
gating and emphasize the importance of interactions be-
tween tm2 and surrounding structural elements with channel
activation.
MATERIALS AND METHODS
Chemicals and synthesis
Fresh acetylcholine (Sigma Chemical Co., St. Louis, MO) stock solutions
were made daily in Ringer’s solution and diluted. Bis-TMP-10 was ob-
tained from Ciba-Geigy (Hawthorne, NY), and TMP was obtained from
Aldrich Chemical Co. (Milwaukee, WI). Bis(2,2,6,6,-tetramethyl-4-piper-
idinyl) succinate (bis-TMP-4) was synthesized by Ciba-Geigy and obtained
from Dr. H. Glossmann (Glossmann et al., 1993). All other chemicals for
electrophysiology were purchased from Sigma. Chemicals used for the
synthesis were purchased from Aldrich. A general synthetic procedure and
the characterization of the synthesized compounds are described below.
General synthetic procedure
To a mixture of 2,2,6,6-tetramethyl-4-piperidinol (3.0 mmol) and one
equivalent of the corresponding ester, unless otherwise specified, in 2 ml of
dimethyl formamide was added 250 mg of powdered potassium carbonate.
The resulting mixture was heated at 145–150°C for 24–72 h under a gentle
stream of N2. After cooling, the reaction mixture was partitioned between
water and methylene chloride. The organic layer was separated, washed
with water and brine, dried (anhydrous MgSO4), and evaporated to dryness
to give a crude product, which was purified via salt formation (HCl or
acetic acid), extraction, or column chromatography. All compounds were
recrystallized before use in electrophysiology experiments.
Bis-TMP-n compounds
These compounds are inhibitors that differ from bis-TMP-10 only in the
length of the aliphatic chain, where n stands for the total number of carbons
in the diester linker. Structures are shown in Fig. 6.
Bis(2,2,6,6-tetramethyl-4-piperidinyl) hexanedioate
(bis-TMP-6)
The title compound was synthesized from dimethyl adipate in 38% yield,
recrystallized from hexane, and then precipitated from hexane as the
acetate salt with a melting point of 135–140°C. 1H NMR (300 MHz, D2O,
): 1.47 (12H, s), 1.51 (12H, s), 1.63 (4H, m), 1.73 (4H, dd, J1  10.6 Hz,
J2  13.6 Hz), 1.90 (4.5H, s), 2.16 (4H, dd, J1  4.1 Hz, J2  14.0 Hz),
2.42 (4H, m), 5.28 (2H, m). 13C NMR (D2O, ): 22.65, 23.84, 25.47, 29.26,
33.84, 39.39, 57.55, 66.13, 175.57, 179.89. LRMS (ESI) 425.3, MH.
Bis(2,2,6,6-tetramethyl-4-piperidinyl) octanedioate
(bis-TMP-8)
The title compound was synthesized from dimethyl octanedioate in 72%
yield and was recrystallized from n-pentane. Melting point was 90°C. 1H
NMR (300 MHz, CDCl3, ): 1.14 (4H, t, J  11.7 Hz), 1.16 (12H, s), 1.24
(12H, s), 1.36 (4H, m), 1.91 (4H, dd, J1 12.6 Hz, J2 4.1 Hz), 2.28 (4H,
t, J 7.4 Hz), 5.19 (2H, tt, J1 11.7 Hz, J2 4.1 Hz); 13C NMR (CDCl3,
): 24.77, 28.71, 28.97, 34.54, 34.80, 43.92, 51.40, 68.52, 173.15; HRMS
(FAB, MH): calculated for C26H49N2O4 453.3692, found 453.3691.
Bis(2,2,6,6-tetramethyl-4-piperidinyl) dodecanedioate
(bis-TMP-12)
The title compound was synthesized from dimethyl dodecanedioate, which
was prepared from dodecanedioic acid and methanol by using thionyl
chloride in 77% yield and was recrystallized from n-pentane. Melting point
was 75–76°C. 1H NMR (CDCl3, ): 1.14 (4H, t, J  11.7 Hz), 1.15 (12H,
s), 1.24 (12H, s), 1.28 (12H, brs), 1.61 (4H, m), 1.91 (4H, dd, J1 12.6 Hz,
J2  4.1 Hz), 2.27 (4H, t, J  7.4 Hz), 5.19 (2H, tt, J1  11.7 Hz, J2 
4.1 Hz); 13C NMR (CDCl3, ): 24.94, 29.00, 29.04, 29.18, 29.32, 34.63,
34.79, 43.93, 51.37, 68.45, 173.26; HRMS (FAB, MH): calculated for
C30H57N2O4 509.4318, found 509.4329.
Preparation of RNA and expression in
Xenopus oocytes
The preparation of in vitro synthesized cRNA transcripts and oocyte
injection have been described previously (Boulter et al., 1987). Briefly, in
vitro cRNA transcripts were prepared using the appropriate mMessage
mMachine kit from Ambion (Austin, TX) after linearization and purifica-
tion of cloned cDNAs. Two to three ovarian lobes were surgically removed
and then cut open to expose the oocytes. The ovarian tissue was then
treated with collagenase from Worthington Biochemical Corp. (Freehold,
NJ) for 2 h at room temperature (in calcium-free Barth’s solution: 88 mM
NaCl, 10 mM HEPES, pH 7.6, 0.33 mM MgSO4, 0.1 mg/ml gentamicin
sulfate). Subsequently, stage 5 oocytes were isolated and injected with 50
nl each of a mixture of the appropriate subunit cRNAs after harvest.
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Recordings were made 2–7 days after injection depending on the cRNAs
being tested.
Electrophysiology
Initial recordings were made on a Warner Instruments (Hamden, CT)
OC-725C oocyte amplifier and RC-8 recording chamber interfaced to a
Macintosh IIcx personal computer, although the majority of experiments
employed a Gene Clamp 500 amplifier (Axon Instruments, Foster City,
CA) interfaced to a Gateway 2000 (North Sioux City, SD) P5–75 personal
computer. Comparable results were obtained on both sets of equipment.
Initial experiments were performed in a configuration such that a 2-ml
bolus of drug was applied after loading of a loop at the terminus of the drug
delivery system, whereas subsequent experiments were conducted in a
configuration where drug application was electronically controlled and
regulated by duration rather than volume, permitting more rapid solution
exchange without stoppage of flow through the chamber. Oocytes were
placed in a Lexan recording chamber with a total volume of 0.6 ml and
perfused at room temperature by frog Ringers (115 mM NaCl, 2.5 mM
KCl, 10 mM HEPES, pH 7.3, 1.8 mM CaCl2) containing 1 M atropine to
block potential muscarinic responses. A Mariotte flask filled with Ringers
was used to maintain a constant hydrostatic pressure for drug deliveries and
washes. Drugs were diluted in perfusion solution and applied from a
reservoir for 10 s using a two-way electronic valve. Data were acquired
using Axoscope 1.1 software (Axon Instruments) at a 20-Hz sample rate
and filtered at a rate of 10 Hz using either a CyberAmp 320 external filter
(Axon Instruments) or the filter in the amplifier. The rate of drug appli-
cation was 6 ml/min in all cases. Current electrodes were filled with a
solution containing 250 mM CsCl, 250 mM CsF, and 100 mM EGTA and
had resistances of 0.5–2 M. Voltage electrodes were filled with 3 M KCl
and had resistances of 1–3 M. Oocytes with resting membrane potentials
more positive than 30 mV were not used.
Experimental protocol and data analysis
Current responses to drug application were studied under two-electrode
voltage clamp at a holding potential of 50 mV unless otherwise noted.
Holding currents immediately before agonist application were subtracted
from measurements of the peak response to agonist. All drug applications
were separated by a wash period for a length of time as noted. At the start
of recording, all oocytes received an initial control application of ACh to
which subsequent drug applications were normalized to control for the
level of channel expression in each oocyte. An experimental application of
ACh with inhibitor was followed by an application of ACh alone 10 min
after the control ACh application used for normalization. In some receptor
subtypes (e.g., 34), rundown was observed to stabilize after a second
application of ACh. For these subtypes, responses were normalized to the
second of two initial control ACh applications. Means and standard errors
(SEMs) were calculated from the normalized responses of at least four
oocytes for each experimental concentration.
For all experiments involving use-dependent inhibitors, a concentration
of ACh was selected sufficient to stimulate the receptors to a level repre-
senting a reasonably high value of popen at the peak of the response, while
minimizing rundown with successive ACh applications. For potent use-
dependent inhibitors, we have found that this concentration is adequate to
achieve maximal inhibition (Francis and Papke, 1996; Papke et al., 1994).
Specific concentrations for each receptor subtype are as noted.
For concentration-response relations, data were plotted using Kaleida-
graph 3.0.2 (Abelbeck Software, Reading, PA), and curves were generated
using the following modified Hill equation (Luetje and Patrick, 1991):
Response
Imaxagonistn
agonistn	 	EC50
n (1)
where Imax denotes the maximal response for a particular agonist/subunit
combination, and n represents the Hill coefficient. Imax, n, and the EC50
were all unconstrained for the fitting procedures, and the r values of the fits
were all 0.96 (the average r value  0.97).
For use-dependent inhibitors, measurements of peak response at the time of
co-application of agonist with inhibitor underestimate steady-state inhibi-
tion in our system. Therefore, in experiments assessing rate of recovery
from use-dependent inhibition (see Fig. 2), inhibitor alone was pre-applied
for a length of time sufficient to achieve maximal concentration in the
chamber before application of agonist. This pre-application protocol max-
imized the probability of block upon channel activation as a function of
inhibitor concentration and permitted the use of peak current as a more
accurate measure of steady-state inhibition for applications of ACh in the
presence of the TMP compounds. After normalization to the control
response (as described above), total inhibition can be calculated by sub-
tracting the normalized value from 1. In this manner, we confirm almost
total inhibition at the time of co-application of agonist with inhibitor and
are able to generate a recovery rate from this point in time. Agonist
concentrations were selected to minimize rundown with successive ACh
applications while still providing a high enough probability of channel
activation during the time course of a response to achieve close to 100%
inhibition and are noted in the figure legend. Recovery rate data were fitted
by the following equation:
% Inhibition I0	et/

 (2)
which describes a first-order process where I0 represents the inhibition at
time t  0 and 
 is the time constant for recovery. The r values of the
displayed fits were all 0.96 (the average r value  0.98).
For experiments assessing voltage dependence of inhibition, oocytes
were initially voltage clamped at a holding potential of 50 mV and a
control application of ACh alone was delivered. The holding potential was
stepped to 20 mV for 30–60 s before co-application of either ACh with
bis-TMP-10 or ACh alone. Thirty to sixty seconds after the peak of the
co-application response, voltage was stepped back down to 50 mV, and
residual inhibition was evaluated with two subsequent applications of ACh
alone separated by 5 min.
For experiments assessing protection from long-term inhibition by
application of a short-term inhibitor, a saturating concentration of the
short-term inhibitor (either QX-314 (lidocaine N-ethyl bromide) or TMP)
was applied for 30–60 s before the application of ACh and the long-term
inhibitor (bis-TMP-10). The application of the short-term inhibitor contin-
ued throughout the time course of the co-application of ACh with long-
term inhibitor until at least 30 s after the co-application. The concentration
of inhibitor and period of application was selected to maximize the poten-
tial for protection effects. Recovery from inhibition was evaluated in 3-min
intervals after the application of inhibitor in the case of 11(4tm2)
receptors and 10 min after application of inhibitor in the case of 34
receptors.
Production of tm2 chimeras and sequencing
Chimeric genes were constructed by the method of overlap extension
polymerase chain reaction (PCR) (Horton et al., 1989). In brief, the genes
1 and 4 were cloned into p-Bluescript SK(). Specific PCR primers
were designed to generate mutants exchanging just the bases necessary to
code the tm2 or ecl region. Each primer contained 27 bases of the sequence
flanking the tm2 or ecl sequence on one side and 24 bases that coded for
the tm2 or ecl region to be exchanged. Oligonucleotides were designed to
contain a unique silent restriction site in the mutant region for future
screening. Separate PCR reactions consisting of the appropriate PCR
primer with template and either T3 or T7 primer selectively amplified the
upstream and downstream portions of the gene of interest with overhanging
chimeric sequence. These two products were then put together in a second
PCR reaction with T3 and T7 primers. The region of chimeric sequence
overlap formed double-stranded DNA that primed elongation in both
directions, and the full-length product was amplified using T3 and T7
primers. The region coding for the mutant sequence was then cut out with
restriction enzymes and cloned back into the original plasmid, reducing the
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amount of PCR-generated sequence in the final constructs. Clones were
evaluated by both restriction analysis and sequencing through the PCR-
generated region by the dideoxy chain termination method (Sanger et al.,
1977) using the Sequenase 2.0 kit from United States Biochemical Corp.
(Cleveland, OH).
RESULTS
Concentration-response relations of
chimeric nAChRs
Chimeric DNAs exchanging sequence coding for eight
amino acids of the tm2 region (underlined below) between
a neuronal -subunit (4) and the muscle -subunit (1)
were constructed by overlap extension PCR. Following the
terminology of Miller (1989) and later Charnet et al. (1991),
the tm2 chimeric region extends from position 4 to position
11, including the position homologous to the inner polar
site of Leonard et al. (1990) at which the charged amino
group of the local anesthetic QX-222 has been hypothesized
to bind in muscle-type nAChRs (position 6). The amino
acid sequences of the membrane-spanning region, from the
intracellular to the extracellular side, are as follows:
These chimeric -subunits were then expressed with the
other muscle subunits (1,,) to produce 11(4tm2)
and 14(1tm2) receptors. The effects of these ex-
changes were initially evaluated in the muscle receptor
because only a single -subunit is included per receptor,
whereas neuronal nAChRs include multiple -subunits. The
presence of a single neuronal -subunit in combination with
the other muscle subunits has been previously shown to be
sufficient for achieving long-term inhibition after co-appli-
cation of bis-TMP-10 with ACh (Papke et al., 1994).
Co-injection of chimeric or wild-type -subunit RNA
with RNA coding for the other muscle subunits provides for
the expression of functional 11, 14,
11(4tm2), and 14(1tm2) receptors with acti-
vation profiles typical of nAChRs. To interpret data com-
paring the magnitude of use-dependent inhibition across
receptor subtypes, it is necessary to first define a relation-
ship between the experimental concentration of agonist
applied and the EC50 for each receptor subtype. Although
the EC50s for each of the receptor subtypes differ some-
what, the Hill coefficients for all of the receptor subtypes
are in the range of 1–2, typical of nAChRs. Although
11, 14, and 14(1tm2) receptors show
comparable EC50s (in the range of 3–8 M),
11(4tm2) receptors require approximately a fivefold
higher concentration of ACh (30 M) for 50% activation.
The concentration of ACh used in specific experiments
ranges between 5 and 30 M depending on receptor type or
experimental design and is noted in the figure legends.
Dependence of long-term inhibition by bis-TMP-
10 on sequence in the tm2 region
The time course of recovery from inhibition by bis-TMP-10
was examined for a number of different subunit combina-
tions (Fig. 1). Although normal muscle-type receptors con-
FIGURE 1 -Subunit tm2 exchange has reciprocal effects on the dura-
tion of inhibition by bis-TMP-10. In each panel, traces representative of the
mean data are shown on the left. The trace marked a is the response to a
co-application of ACh with inhibitor, and the trace marked b is the
response to ACh alone 5 min later and is used as a measure of recovery
from inhibition. To generate mean data, the co-application (a) and recovery
(b) responses are normalized to the trace marked control. Mean data are
displayed in the bar graphs on the right. In each graph, the pair of bars on
the left (a) represent the normalized response to a co-application of ACh
with 2 M bis-TMP-10 and correspond to the trace marked a at left. The
pair of bars on the right (b) represent the normalized response to an
application of ACh alone 5 min after the co-application response and
correspond to the trace marked b at left. Each column represents the mean
response  SEM of at least four oocytes injected with RNA coding for
either: (A) 11 ( ) or 1(4tm2) ( ); (B) 14 ( ) or
14(1tm2) ( ); (C) 34 ( ) or 34(1tm2) ( ) nAChRs. The
concentration of ACh in each experiment is either 30 M (A and B) or 100
M (C). All responses are separated by 5-min wash intervals.
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sistently recover from inhibition within 5 min after co-
application of 30 M ACh and 2 M inhibitor,
11(4tm2) chimeric receptors show more prolonged
inhibition (Fig. 1 A). To demonstrate a reciprocal depen-
dence of this effect, the time course of recovery from
inhibition of 14 receptors after co-application of 2 M
bis-TMP-10 and 30 M ACh was compared with that of
14(1tm2) receptors (Fig. 1 B). Whereas 14
receptors remain 73% inhibited after 5 min,
14(1tm2) receptors recover to near control levels.
Additionally, coexpression of the neuronal 3 subunit with
the chimeric 4(1tm2) subunit produces receptors that
recover completely from inhibition within 5 min, whereas
normal 34 receptors are still 93% inhibited (Fig. 1 C).
It should also be noted that continuous application of 2 M
bis-TMP-10 to 14(1tm2) receptors for up to 1 min in
duration without co-application of agonist does not produce
any significant inhibitory effects, indicating the use depen-
dence of inhibition (data not shown).
The rapid recovery of 34(1tm2) receptors from inhi-
bition by bis-TMP-10 indicates that the neuronal 3 subunit
is insensitive to long-term inhibition after application of
bis-TMP-10. The sensitivities of the neuronal 2 and 4
subunits to inhibition by bis-TMP-10 were also evaluated.
Although attempts to get expression of 44(1tm2) recep-
tors were unsuccessful, 24(1tm2) receptors recover
completely within 5 min from the inhibition elicited with
co-application of 30 M ACh and 2 M bis-TMP-10 (data
not shown). As the 4 and 2 subunits are identical within
the tm2 domains, it is hypothesized that -subunits do not
play a role in determining sensitivity to long-term inhibition
by bis-TMP-10.
A chimeric -subunit in which a sequence from the
putative ecl region between tm2 and tm3 of a neuronal 4
subunit was replaced with the homologous sequence from
the muscle 1 subunit (shown in bold above) was also
constructed. The bis-TMP-10 sensitivity of receptors result-
ing from coexpression of the 4(1ecl) subunit with either
the other muscle subunits (, , and ) or the neuronal 3
subunit was evaluated. The substitution of the 1 ecl se-
quence does not reverse the long-term inhibition normally
observed with co-application of bis-TMP-10 and ACh to
either the 14 or 34 subunit combinations. Five
minutes after co-application of 2 M bis-TMP-10 with an
appropriate concentration of ACh (10 or 100 M, respec-
tively), the responses of 14(1ecl) (n  3) and
34(1ecl) receptors (n  4) recover to only 13  02%
and 7 01% of initial control responses to ACh alone (data
not shown).
To examine the rate of recovery from inhibition for
individual receptor subtypes, ACh was applied at time
points beyond 5 min after co-application of ACh with
bis-TMP-10 and residual inhibition was evaluated (Fig. 2).
For these experiments, 2 M bis-TMP-10 alone was applied
continuously for 15–20 s before application of ACh in the
continued presence of 2 M bis-TMP-10. The ACh con-
centrations used were either 10 M for the 11,
14, 11(4tm2), or 14(1tm2) subunit com-
binations or 100 M ACh for 34 receptors. Muscle-type
receptors show the most rapid recovery from inhibition with
a time constant of recovery (
r) of 3 min, whereas chi-
meric 11(4tm2) receptors exhibit the most prolonged
inhibition (
r  81 min). As expected, 34 receptors also
show prolonged inhibition with a time constant of recovery
of 70 min. The rate of recovery of 14(1tm2) re-
ceptors (
r  6 min) is most comparable to that of muscle-
type receptors, whereas the recovery rate of 14 recep-
tors falls in an intermediate range (
r  16 min).
Inhibition is independent of voltage
As the residence time of the previously characterized open-
channel blockers QX-222 and QX-314 has been shown to
be dependent on membrane voltage (Leonard et al., 1988;
Neher and Steinbach, 1978) and block by a variety of
bis-ammonium compounds has also been shown to be volt-
age-dependent (Ascher et al., 1979; Bertrand et al., 1990;
Zhorov et al., 1991), we hypothesized that inhibition by
bis-TMP-10 should also show voltage dependence if inhi-
bition occurs via binding to the chimeric tm2 region directly.
FIGURE 2 Recovery from inhibition by bis-TMP-10 as a function of
time. The data points at t  0 min represent a measure of total inhibition
observed after co-application of ACh with 2 M bis-TMP-10 (see Mate-
rials and Methods). Data points at t  5, t  10, or t  15 min represent
mean values of residual inhibition measured after application of ACh
alone. For 11 receptors, full recovery was effectively achieved after
only 10 min of wash, so the data at the 15-min time point for this receptor
subtype is omitted for clarity. All drug applications are separated by 5-min
wash periods. The concentration of ACh in each experiment is either 10
M (11, 1(4tm2), 14, and 14(1tm2)) or 100 M
(34 and 34(1tm2). All data points represent the mean responses of
at least four oocytes and are fit with an equation describing exponential
recovery (see Materials and Methods). In some cases (e.g., 11), the
recovery process appears to contain two components. However, the nor-
malized responses at later time points reflect the minimal contribution of
response rundown over time.
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As 11(4tm2) receptors resemble neuronal
nAChRs in their time course of recovery from inhibition but
maintain the linear current-voltage relationship typical of
muscle-type nAChRs (Fig. 3 A, bottom), it is possible to
examine the effects of voltage on sensitivity to inhibition
independent of voltage effects on channel gating. A voltage
step to 20 mV for the duration of the co-application of 30
M ACh with 2 M bis-TMP-10 does not increase the rate
of recovery of 11(4tm2) receptors from inhibition or
significantly reduce the relative magnitude of inhibition
from that observed with a steady holding potential of 50
mV (Fig. 3, A and C). Thus, the binding of bis-TMP-10 to
its activation-sensitive site appears to be independent of
membrane voltage in 11(4tm2) receptors.
The same paradigm was used to examine the dependence
of inhibition on membrane voltage for the 34 receptor
subtype (Fig. 3 B). However, as neuronal receptors show
pronounced inward rectification (Fig. 3 B, bottom), a lack of
inhibition at positive potentials may result from either a
voltage dependence of inhibition itself or a voltage depen-
dence for channel opening. Although neuronal nAChRs
pass very little outward current at depolarized potentials, a
co-application of 100 M ACh with 2 M bis-TMP-10
during a voltage step to 20 mV produces 75% residual
inhibition as assessed with application of ACh alone at a
holding potential of 50 mV 5 min after co-application of
inhibitor with ACh (Fig. 3 B, lower trace, and Fig. 3 C).
This inhibition is clearly independent of the minimal run-
down observed with control applications of ACh alone (Fig.
3 B, upper trace).
Open-channel blockers do not protect nAChRs
from long-term inhibition by bis-TMP-10
Although the -subunit tm2 chimeras demonstrate a depen-
dence of inhibition on sequence in the tm2 region, the lack
of voltage dependence for this inhibition suggests an indi-
rect effect of the tm2 region rather than binding of the
inhibitor directly to this region. We hypothesized that, if
bis-TMP-10 binds to the tm2 region directly, a pre-applica-
tion of the previously characterized open-channel blocker
lidocaine N-ethyl bromide (QX-314) should protect from
long-term inhibition. To evaluate this hypothesis for chi-
meric 11(4tm2) receptors, we applied 100 M QX-
314 alone continuously for 1 min before and throughout a
10-s co-application of 2 M bis-TMP-10 with 5 M ACh
until 1 min after the co-application of agonist and long-term
inhibitor (Fig. 4 A). Residual inhibition was then evaluated
with applications of ACh alone at 3 and 6 min after co-
application of ACh with inhibitor (Fig. 4, A and C). Al-
FIGURE 3 Long-term inhibition of either 11(4tm2) (A) or 34
(B) receptors by bis-TMP-10 is independent of voltage. In the representa-
tive traces of A and B, an initial control application of either 30 M (A) or
100 M (B) ACh is followed by either successive applications of ACh
alone (upper trace) or by a single co-application of ACh with 2 M
bis-TMP-10 followed by subsequent application of ACh alone (lower
trace). The timing of the voltage step from 50 mV to 20 mV is
represented by and begins 30 s before and ends 30 s after the peak
of the co-application response in each case. Five-minute wash periods
separate each response. Representative current-voltage relationships for
each of these receptor subtypes during the plateau phase of the response to
extended application of either 30 or 100 M ACh are also shown. As
measured from the I-V relationships, the mean reversal potential for
11(4tm2) receptors is 4.0  2.1 mV (n  3) and for 34
receptors is11.0 2.3 mV (n 4). Holding currents during ramps in the
absence of agonist were point to point subtracted. In C, mean normalized
data for the 5-min time point (corresponding to traces at far right in A and
B above) are shown. Each pair of bars represents the normalized response
of either 11(4tm2) ( ) or 34 ( ) receptors to application of either
30 M (11(4tm2)) or 100 M (34) ACh alone at a holding
potential of 50 mV 5 min after one of three experimental conditions,
from left to right: 1) application of ACh alone during a voltage step to20
mV, 2) co-application of ACh with bis-TMP-10 during a voltage step to
20 mV, or 3) co-application of ACh with bis-TMP-10 at a constant
holding potential of 50 mV.
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though this receptor subtype consistently recovers within 3
min from inhibition elicited using the same application
paradigm without the bis-TMP-10 application (middle
trace), co-application of bis-TMP-10 in the presence of
QX-314 consistently produces long-term inhibition (90%
at t  3 min) that is not significantly different from control
applications of bis-TMP-10 with ACh (compare upper and
lower traces). These results demonstrate a lack of effect of
QX-314 on inhibition by bis-TMP-10. However, because of
the potential for multiple intraburst blocking and unblock-
ing events during the time course of agonist application in
the presence of the short-term inhibitor, we also repeated the
experiment at higher concentrations of QX-314 (up to 500
M) and at more negative potentials. No protection from
long-term inhibition was observed with voltage steps to
80 mV or applications of 500 M QX-314 (n  3; data
not shown).
The effects of the monofunctional inhibitor TMP (30
M) on long-term inhibition of 11(4tm2) receptors
were also evaluated using the same application paradigm
(Fig. 4 B). TMP is able to produce 30% protection from
long-term inhibition. These results are summarized in
Fig. 4 C.
A similar set of experiments was conducted on the 34
receptor subtype. The co-application of short- and long-
term inhibitors was conducted in the same manner as de-
scribed above. Application of 500 M QX-314 produces a
small amount of protection (18%) from long-term inhibi-
tion by bis-TMP-10 (Fig. 5 A), whereas application of 4 M
TMP with bis-TMP-10 (Fig. 5 B) limits long-term inhibition
to a level that is not significantly different from that ob-
served with application of only the short-term inhibitor
TMP. These results are summarized in Fig. 5 C.
Long-term inhibition is dependent upon
compound length
If binding of both TMP moieties of the bifunctional com-
pounds is necessary for long-term inhibition, we reasoned
that the distance between TMP moieties might represent a
constraint on inhibitory activity. To test this hypothesis, the
amount of inhibition remaining at time points 5 and 10 min
after co-application of inhibitor with ACh to either chimeric
11(4tm2) or neuronal 34 receptors was assessed
FIGURE 4 Effects of presence of short-term inhibitors on long-term
inhibition of 11(4tm2) receptors. In the representative traces of A
and B, the thick lines above the traces indicate the duration of agonist
and/or inhibitor application. In each set of three traces of A, the first trace
(from left) represents the response to a 10-s application of 5 M ACh ( ),
whereas the second trace (from left) represents the response to either a
co-application of 5 M ACh with 2 M bis-TMP-10 ( , upper), an
application of 5 M ACh in the continued presence of 100 M QX-314
( , middle), or 5 M ACh co-applied with 2 M bis-TMP-10 in the
continued presence of 100 M QX-314 (lower). In each set of three traces
of B, the first trace (from left) represents the response to 5 M ACh,
whereas the second trace (from left) represents the response to either an
application of 5 M ACh in the continued presence of 30 M TMP ( ,
upper) or a co-application of 5 M ACh with 2 M bis-TMP-10 in the
continued presence of 30 M TMP (lower). In all cases, the third trace
(from left) represents the response to ACh alone applied after a 3-min wash
period. The scatter plot in C displays the mean normalized responses 
SEM of at least four oocytes as a function of time. The points at t  0 min
correspond to the second trace (from left) in each of the sets of traces
above: bis-TMP-10 with ACh (), QX-314 with ACh (E), ACh with
QX-314 and bis-TMP-10 (F), TMP with ACh (‚), and ACh with TMP and
bis-TMP-10 (Œ);, the response to successive applications of ACh alone.
The data points at 3 and 6 min show the mean responses to ACh alone after
washout of inhibitor and are used as measures of recovery from inhibition.
Overlapping plot symbols were shifted by 30 s to aid in the viewing of
all data points.
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for bifunctional TMP molecules differing only in the length
of their carbon linker. TMP, bis-TMP-4, bis-TMP-6, bis-
TMP-8, bis-TMP-10, and bis-TMP-12 were tested for their
inhibitory effects (Fig. 6). For both receptor subtypes, all of
the compounds, including the monofunctional inhibitor
TMP, show some inhibitory activity at the time of co-
application with ACh. However, no significant residual
inhibition of 11(4tm2) receptors results from co-
application with ACh of compounds with linkers of eight
carbons or less whereas pronounced residual inhibition is
present after application of inhibitors with linkers of 10 or
more carbons. In contrast, for neuronal nAChRs (34), all
bifunctional compounds show some degree of residual in-
hibitory activity at time points 5 and 10 min after the time
of co-application with ACh (Fig. 6, bottom), and the mag-
nitude of residual inhibition increases with increasing com-
pound length. These results are consistent with binding of
each of the piperidinyl groups to distinct sites separated by
a characteristic length specific to each subunit combination.
Based on previous work demonstrating that the -subunit
of muscle-type nAChRs is sensitive to the TMP moiety
(Francis and Papke, 1996), we reasoned that distinct sites
might be represented on separate subunits. To demonstrate
a requirement for contributions by at least two TMP-sensi-
tive subunits for long-term inhibition, it was necessary to
examine the time course of recovery from inhibition of
receptors containing only a single sensitive subunit.
11(4tm2) receptors show no measurable residual in-
hibition 5 min after co-application of 30 M ACh with 2
M bis-TMP-8 (n  4) or 2 M bis-TMP-10 (n  6; data
not shown).
DISCUSSION
A great deal of research has employed the use of noncom-
petitive inhibitors to explore the relationship between struc-
ture and function in ion channels. The muscle-type/Torpedo
nAChR is the prototype system for these studies both be-
cause of its ready availability in purifiable quantities and the
rigorous characterization of its functional role at the neuro-
muscular junction. By examining the mechanism of inhibi-
tion of a class of drugs that show selectivity for the long-
term inhibition of neuronal nAChRs, we attempt to extend
the analysis of structure-function relationships to neuronal
FIGURE 5 Effects of presence of short-term inhibitors on long-term
inhibition of 34 receptors. In the representative traces of A and B, the
thick lines above the traces indicate the duration of agonist and/or inhibitor
application. In each set of three traces of A, the first trace (from left)
represents the response to a 10-s application of 100 M ACh
( ), whereas the second trace (from left) represents the response to either
a co-application of 100 M ACh with 2 M bis-TMP-10 ( , upper), an
application of 100 M ACh in the continued presence of 500 M QX-314
( , middle), or 100 M ACh co-applied with 2 M bis-TMP-10 in the
continued presence of 500 M QX-314 (lower). In each set of three traces
of B, the first trace (from left) represents the response to 100 M ACh,
whereas the second trace (from left) represents the response to either an
application of 100 M ACh in the continued presence of 4 M TMP ( ,
upper trace) or a co-application of 100 M ACh with 2 M bis-TMP-10
in the continued presence of 4 M TMP (lower trace). In all cases, the third
trace (from left) represents the response to an application of 100 M ACh
alone after a 10-min wash period. The scatter plot in C displays the mean
normalized responses SEM of at least four oocytes as a function of time.
The points at t  0 min correspond to the second trace (from left) in each
of the sets of traces above: bis-TMP-10 with ACh ([), QX-314 with ACh
([E), ACh with QX-314 and bis-TMP-10 (F), TMP with ACh (‚), and
ACh with TMP and bis-TMP-10 (Œ); , the response to successive
applications of ACh alone. The data points at 10 min show the mean
responses to ACh alone after washout of inhibitor and are used as measures
of recovery from inhibition. Overlapping plot symbols at t  0 min were
shifted in time to aid in the viewing of all data points.
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nAChRs. Interestingly, our data demonstrate that long-term
inhibition is strictly use dependent within the time frame of
our application of inhibitor but apparently not associated
with direct binding to site(s) situated within the portion of
the ion channel pore influenced by the membrane electric
field. The most parsimonious interpretation of these data
allows for interactions upon channel activation between
residues located within the tm2 region of neuronal -sub-
units and sequence elements situated outside of the mem-
brane electric field. It is possible that these interactions, in
turn, result in the exposure of the use-dependent binding
site(s) for bis-TMP-10.
TM2 determines kinetics of long-term inhibition
Our studies examining the time course of inhibition of
receptors containing chimeric -subunits localize the major
structural determinant of sensitivity to long-term inhibition
to an eight-amino-acid stretch of neuronal -subunits. All
receptor subtypes tested that incorporate the neuronal
-subunit tm2 region paired with either a second neuronal
-subunit (neuronal nAChRs) or a -subunit (neuronal-
muscle chimeras) exhibit a significant degree of residual
inhibition as measured at time points 5 min or more after the
co-application of agonist with inhibitor. The reversal of
long-term inhibition upon substitution of the 1 subunit tm2
region for the 4 subunit tm2 region in 14(1tm2) and
34(1tm2) receptors in conjunction with the observation
that substitution of the 1 ecl region does not reverse
long-term inhibition demonstrates this effect to be specific
for the tm2 region. Although 14 receptors exhibit
prolonged inhibition compared with 14(1tm2) or
muscle-type receptors (Fig. 2), they recover from inhibition
more rapidly than the 11(4tm2) or 14(1ecl)
receptor subtypes. Taken together, these observations per-
haps suggest that, when associated with the other muscle
subunits in 14 receptors, regions of the 4 subunit not
contained within the tm2 domain may affect the binding of
inhibitor directly or otherwise allow for increased recovery
rate. The 4 subunit has been shown to confer the property
FIGURE 6 The effects of compound length on long-term inhibition of 11(4tm2) and 34 nAChRs. All data points represent the mean peak
response  SEM of at least four oocytes normalized to an initial control response to ACh alone. In each graph, the data point at t  0 min represents the
normalized response to co-application of either a 4 M concentration of the monofunctional compound (TMP, left) or a 2 M concentration of the
bifunctional compounds with 30 M ACh. The data points at t  5 and t  10 min represent the normalized responses to 30 M ACh alone after washout
of inhibitor and are used as measures of recovery from inhibition. It should be noted that, in these experiments, measures of relative inhibition of peak
current at t  0 min do not quantitate steady-state inhibition (see Materials and Methods) but serve to demonstrate the fundamental sensitivity of both
receptor subtypes to the TMP compounds. For this reason, the data points at t  0 min are connected to the 5-min data points by a dashed line.
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of prolonged burst kinetics upon the neuronal subunits with
which it is expressed (Papke and Heinemann, 1991). It may
be the case that activation properties such as burst duration
or channel open time, which may be specific to individual
receptor subtypes, can also influence recovery rate or the
probability of block as a function of peak current.
Significance of voltage-independent inhibition
In contrast to studies on the open-channel blockers QX-222
and QX-314 (Neher and Steinbach, 1978) and studies on the
symmetrical bis-ammonium series of ganglionic blockers
(Ascher et al., 1979) in which block has been shown to be
dependent on membrane potential, the inhibition by bis-
TMP-10 seems to be independent of voltage. The lack of
voltage dependence for inhibition brings to mind two pos-
sibilities: either the noncompetitive binding site is outside of
the membrane electric field or bis-TMP-10 is uncharged at
physiological pH. Although direct evaluation of the pKa of
bis-TMP-10 has not been possible because of solubility
limitations, it is known that the monofunctional inhibitor
TMP has a pKa in the range of 10–11 (Perrin, 1965). The
pKa of simple bis-amino compounds are reduced if the
amines are separated by short (two to four) carbon chains.
However, when the amines are separated by a longer (e.g.,
eight) carbon chain, the pKa values of the two ionizable
groups both approach that of the monofunctional amine.
Therefore, with the pKa of the monofunctional piperidine in
the range of 10–11, it is unlikely that the lower of the 2 pKa
values of the bis compound would be under 9–10. Thus, at
physiological pH, both functional groups should be predom-
inantly charged.
The voltage-independent long-term inhibition of 34
receptors is particularly intriguing. As shown in Fig. 3 C,
the inhibition observed 5 min after the co-application of
agonist with inhibitor at 20 mV (75%) is slightly less
than that typically observed 5 min after co-applications of
ACh with bis-TMP-10 at50 mV (90%). This effect may
represent a voltage-dependent component of long-term in-
hibition but more likely represents an effect of the voltage
dependence of channel gating independent of any voltage
dependence for inhibition. In either case, at this potential, no
outward current was measured in response to control appli-
cations of ACh alone, implying that the activation-depen-
dent state associated with inhibition is distinct from the
conducting state. The inward rectification of neuronal nAChRs
is due, at least in part, to a magnesium block dependent upon
the sequence at the cytosolic mouth of the channel (Ifune and
Steinbach, 1992; Imoto et al., 1988; Sands and Barish, 1992).
Our data suggest that a gating conformation may still be
present at depolarized potentials and are consistent with chan-
nel block by magnesium from the intracellular side. Thus,
bis-TMP-10 appears to be able to produce long-term inhibition
of neuronal nAChRs that are gated (or activated) but noncon-
ducting as a result of block from the intracellular side. Alter-
natively, it may be the case that a high-affinity desensitized
state is favored at depolarized potentials in the presence of
agonist. Our data would suggest that a gated conformation is
associated with this state as well.
We also tested the hypothesis that bis-TMP-10 can pro-
duce long-term inhibition in nAChRs that are nonconduct-
ing as a result of blockade from the extracellular side. We
chose to use the open-channel blocker QX-314 in these exper-
iments based upon three criteria: 1) the QX-314 binding site is
believed to be located approximately three-fourths of the way
across the membrane electric field, and thus inhibition by this
compound is voltage dependent (Neher and Steinbach, 1978);
2) QX-314 has been shown to interact with residues at homol-
ogous positions to those contained within the region of our
-subunit tm2 chimeras (Pascual and Karlin, 1997); and 3)
QX-314 has a longer residence time in the pore than the
structurally related local anesthetic QX-222 (Neher and Stein-
bach, 1978). In addition, studies in our laboratory have shown
that the inhibition of chimeric 11(4tm2) receptors by
QX-314 is voltage dependent, indicating that, for this subunit
combination also, the QX-314 binding site is located within the
membrane electric field (M.M. Francis and R.L. Papke, un-
published observations).
For 11(4tm2) receptors, the lack of an effect of
even very high concentrations of QX-314 (500 M) on the
magnitude of residual inhibition after co-application of bis-
TMP-10 with ACh is consistent with the observed voltage
independence of inhibition by bis TMP-10. For 34 recep-
tors, QX-314 does produce a detectable reduction in the mag-
nitude of residual inhibition (Fig. 5 C). This observation sug-
gests that in this subunit combination the sites of action for
bis-TMP-10 and QX-314 are not totally independent. From our
data, it is difficult to ascertain whether the partial protection we
observe represents interactions of both drugs at a single site or,
alternatively, an allosteric interaction between two distinct
sites, such that the binding of QX-314 decreases the gating-
dependent changes at the site of TMP binding.
For both receptor subtypes, the short-term inhibitor TMP
produces a significantly greater degree of protection from
long-term inhibition than was observed with QX-314. This
finding demonstrates a degree of overlap in the sites of
action between the mono- and bifunctional compounds. The
lack of complete protection may suggest a contribution of
the hydrophobic linker region in stabilizing bis-TMP-10
binding or may indicate that a different subset of binding
sites are available to the smaller TMP compound. The latter
hypothesis is supported by the observation of a slight volt-
age dependence for inhibition by TMP (Papke et al., 1994).
Significance of compound length requirement for
long-term inhibition
We have previously shown that  receptors are sensitive
to long-term inhibition by bis-TMP-10. Based on these data,
we hypothesized that a TMP binding site is present on the
-subunit of muscle-type nAChRs and that long-term inhi-
bition occurs via interactions at multiple sites (Francis and
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Papke, 1996). Consistent with this hypothesis, we now
present data that suggest that substitution of the muscle
-subunit tm2 sequence with the neuronal -subunit tm2
sequence results in the exposure of a second TMP binding
site located outside of the membrane electric field. Further-
more, because long-term inhibition is dependent upon the
sequence in tm2 for both chimeric muscle and chimeric
neuronal receptors, it seems reasonable that the inhibitor
binding site may represent a structural motif that is con-
served across classes of -subunits. For the -subunit of
muscle-type nAChRs, it has been shown that channel acti-
vation alters the accessibility of substituted cysteines at
positions immediately extracellular to the region of our
chimera (Zhang and Karlin, 1996). It may be the case that
these residues contribute to a binding site for bis-TMP-10.
The results of both the voltage dependence and protection
experiments localize the majority of bis-TMP-10 effects to
sites lying outside the membrane electric field. Given the
data, it seems logical to speculate that these sites lie on the
extracellular portion of the receptor, possibly as a part of the
protein domains forming the extracellular vestibule. In its
most extended conformation, bis-TMP-10 is estimated to
have a length of between 20 and 23 Å. This estimate of
length is consistent with binding to sites on separate sub-
units in the wider, extracellular portion of the channel.
Nonetheless, it may be the case that, in addition to tethering
the piperidinyl groups, the flexible linker region of the
bis-TMP compounds serves to stabilize binding via hydro-
phobic interactions, and differences in this form of interac-
tion could underlie some of the sensitivity differences be-
tween the chimeras and the neuronal receptors. The relative
importance of hydrophobic versus polar groups in stabiliz-
ing the interactions between bis-TMP-10 and its binding
site(s) is currently under investigation, and these data will
be presented elsewhere.
If the primary function of the linker region is to serve as
a tether between active inhibitory moieties, then the differ-
ences in size constraints may provide some insight into the
disposition of sensitive subunits within a receptor complex.
Although a number of studies have provided evidence that
the -subunit is situated adjacent to the -subunit in Tor-
pedo nAChRs (Holtzman et al., 1981; Karlin et al., 1983;
Machold et al., 1995), comparable data are lacking for
muscle receptors, either in vivo or in heterologous expres-
sion systems. Our results demonstrate that both a minimal
10-carbon distance between TMP moieties and the presence
of the -subunit are required for effective long-term inhibi-
tion of 11(4tm2) receptors. In contrast to the less
stringent length requirement for long-term inhibition of
neuronal receptors, the requirement for a long linker to
achieve long-term inhibition of 11(4tm2) receptors
seems most consistent with a model in which the distance
between the TMP moieties of an extended conformation of
bis-TMP-10 represents the distance between opposing
rather than adjacent - and -subunits. However, our data to
this point cannot absolutely rule out the alternative possi-
bility that the inhibitor binds to asymmetrically disposed
sites on adjacent subunits.
In summary, our results demonstrate that the selective
long-term inhibition of neuronal nicotinic receptors by bis-
TMP-10 is dependent upon the sequence in the tm2 region.
We show, however, that long-term inhibition is apparently
independent of binding to this region directly. Because
inhibition depends upon previous activation of the channel,
our results imply that bis-TMP-10 binds to a structural
element that may become available as a result of the con-
formational change associated with channel gating. The
observed compound length requirements are consistent with
binding to an extracellular site. Future studies employing
this class of inhibitors and functional analogs in conjunction
with other techniques may add unique insights to the struc-
tural changes that take place with channel gating.
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